A Multicenter Retrospective Study of the Risk Factors Associated with Medication-related Osteonecrosis of the Jaw After Tooth Extraction in Patients Receiving Oral Bisphosphonate Therapy: Can Primary Wound Closure and a Drug Holiday Really Prevent...

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2017 Apr 29

PMID 28451732

Citations 58

Authors

T Hasegawa

A Kawakita

N Ueda

R Funahara

A Tachibana

M Kobayashi

E Kondou

D Takeda

Y Kojima

S Sato

S Yanamoto

H Komatsubara

M Umeda

T Kirita

H Kurita

Y Shibuya

T Komori

Affiliations

Soon will be listed here.

Abstract

Introduction: Osteonecrosis of the jaws can occur following tooth extraction in patients receiving bisphosphonate drugs. Various strategies for minimizing the risk of MRONJ have been advanced, but no studies have comprehensively analyzed the efficacy of factors such as primary wound closure, demographics, and drug holidays in reducing its incidence. The purpose of this study was to retrospectively investigate the relationships between these various risk factors after tooth extraction in patients receiving oral bisphosphonate therapy.

Methods: Risk factors for MRONJ after tooth extraction were evaluated using univariate and multivariate analysis. All patients were investigated with regard to demographics; type and duration of oral bisphosphonate use; whether they underwent a discontinuation of oral bisphosphonates before tooth extraction (drug holiday), and the duration of such discontinuation; and whether any additional surgical procedures (e.g., incision, removal of bone edges, root amputation) were performed.

Results: We found that root amputation (OR = 6.64), extraction of a single tooth (OR = 3.70), bone loss or severe tooth mobility (OR = 3.60), and an unclosed wound (OR = 2.51) were significantly associated with increased risk of developing MRONJ.

Conclusions: We recommend a minimally traumatic extraction technique, removal of any bone edges, and mucosal wound closure as standard procedures in patients receiving bisphosphonates. We find no evidence supporting the efficacy of a pre-extraction short-term drug holiday from oral bisphosphonates in reducing the risk of MRONJ.

Citing Articles

Autologous and Heterologous Minor and Major Bone Regeneration with Platelet-Derived Growth Factors.

Dipalma G, Inchingolo A, Colonna V, Marotti P, Carone C, Ferrante L J Funct Biomater. 2025; 16(1).

PMID: 39852572 PMC: 11765672. DOI: 10.3390/jfb16010016.

Bertoldo F, Eller-Vainicher C, Fusco V, Mauceri R, Pepe J, Bedogni A J Bone Oncol. 2025; 50():100656.

PMID: 39807373 PMC: 11728904. DOI: 10.1016/j.jbo.2024.100656.

Ruan H, Li M, Zhang Z, Ma H, He Y Clin Oral Investig. 2024; 28(10):549.

PMID: 39317736 PMC: 11422288. DOI: 10.1007/s00784-024-05911-z.

A Systematic Review of Laser Photobiomodulation Dosimetry and Treatment Protocols in the Management of Medications-Related Osteonecrosis of the Jaws: A Rationalised Consensus for Future Randomised Controlled Clinical Trials.

Hanna R, Miron I, Dalvi S, Arany P, Bensadoun R, Benedicenti S Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204116 PMC: 11357434. DOI: 10.3390/ph17081011.

Survey of the association between tooth extraction and development of medication-related osteonecrosis of the jaw in patients undergoing cancer treatment with bone-modifying agents.

Nozawa-Kobayashi M, Sakuma H, Kanemaru H, Kurokawa A, Soga M, Yamashita M Oral Maxillofac Surg. 2024; 28(2):849-857.

PMID: 38296902 DOI: 10.1007/s10006-024-01221-6.

References

Walter C, Klein M, Pabst A, Al-Nawas B, Duschner H, Ziebart T . Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig. 2009; 14(1):35-41. DOI: 10.1007/s00784-009-0266-4. View

Mavrokokki T, Cheng A, Stein B, Goss A . Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007; 65(3):415-23. DOI: 10.1016/j.joms.2006.10.061. View

Acil Y, Moller B, Niehoff P, Rachko K, Gassling V, Wiltfang J . The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells. J Craniomaxillofac Surg. 2011; 40(8):e229-35. DOI: 10.1016/j.jcms.2011.10.024. View

Malden N, Beltes C, Lopes V . Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm. Br Dent J. 2009; 206(2):93-8. DOI: 10.1038/sj.bdj.2009.5. View

Saia G, Blandamura S, Bettini G, Tronchet A, Totola A, Bedogni G . Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J Oral Maxillofac Surg. 2010; 68(4):797-804. DOI: 10.1016/j.joms.2009.10.026. View

Khosla S, Burr D, Cauley J, Dempster D, Ebeling P, Felsenberg D . Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22(10):1479-91. DOI: 10.1359/jbmr.0707onj. View

Roelofs A, Coxon F, Ebetino F, Lundy M, Henneman Z, Nancollas G . Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res. 2010; 25(3):606-16. PMC: 3153397. DOI: 10.1359/jbmr.091009. View

Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S . Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008; 66(5):839-47. PMC: 2426967. DOI: 10.1016/j.joms.2008.01.026. View

Ferlito S, Liardo C, Puzzo S . Dental extractions in patient treated with intravenous bisphosphonates and risk of osteonecrosis of jaws: presentation of a preventive protocol and case series. Minerva Stomatol. 2011; 59(11-12):593-601. View

10.

Kanis J, Gertz B, Singer F, Ortolani S . Rationale for the use of alendronate in osteoporosis. Osteoporos Int. 1995; 5(1):1-13. DOI: 10.1007/BF01623652. View

11.

Migliorati C . Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol. 2003; 21(22):4253-4. DOI: 10.1200/JCO.2003.99.132. View

12.

Vescovi P, Campisi G, Fusco V, Mergoni G, Manfredi M, Merigo E . Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol. 2011; 47(3):191-4. DOI: 10.1016/j.oraloncology.2010.11.007. View

13.

Ruggiero S, Dodson T, Fantasia J, Goodday R, Aghaloo T, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72(10):1938-56. DOI: 10.1016/j.joms.2014.04.031. View

14.

Curtis J, Westfall A, Cheng H, Delzell E, Saag K . Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int. 2008; 19(11):1613-20. PMC: 2574626. DOI: 10.1007/s00198-008-0604-4. View

15.

Katsarelis H, Shah N, Dhariwal D, Pazianas M . Infection and medication-related osteonecrosis of the jaw. J Dent Res. 2015; 94(4):534-9. DOI: 10.1177/0022034515572021. View

16.

Damm D, Jones D . Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. Gen Dent. 2013; 61(5):33-8. View

17.

Khan A, Morrison A, Hanley D, Felsenberg D, McCauley L, ORyan F . Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2014; 30(1):3-23. DOI: 10.1002/jbmr.2405. View

18.

Otto S, Pautke C, Opelz C, Westphal I, Drosse I, Schwager J . Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg. 2010; 68(11):2837-45. DOI: 10.1016/j.joms.2010.07.017. View

19.

Filleul O, Crompot E, Saussez S . Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol. 2010; 136(8):1117-24. DOI: 10.1007/s00432-010-0907-7. View

20.

Bodem J, Kargus S, Eckstein S, Saure D, Engel M, Hoffmann J . Incidence of bisphosphonate-related osteonecrosis of the jaw in high-risk patients undergoing surgical tooth extraction. J Craniomaxillofac Surg. 2015; 43(4):510-4. DOI: 10.1016/j.jcms.2015.02.018. View